^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Non Small Cell Lung Cancer
    Regimen:DP (cisplatin + docetaxel)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/11/2019
    Excerpt:
    Docetaxel Injection is a microtubule inhibitor indicated for:...Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Adenocarcinoma, large cell, NSCLC NOS…Other recommended… cisplatin/docetaxel